Bionano Genomics Inc (NASDAQ: BNGO) has experienced a decline in its stock price by -0.88% compared to its previous closing price of $3.4. However, the company has seen a gain of 2.43% in its stock price over the last five trading days. globenewswire.com reported 2025-05-19 that SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) — Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party payers.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
Moreover, the 36-month beta value for BNGO is 2.07. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy”, 2 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for BNGO is 3.35M and currently, short sellers hold a 16.39% of that float. On July 04, 2025, BNGO’s average trading volume was 138.91K shares.
BNGO’s Market Performance
BNGO stock saw a decrease of 2.43% in the past week, with a monthly decline of -8.67% and a quarterly a decrease of -10.13%. The volatility ratio for the week is 4.45%, and the volatility levels for the last 30 days are 4.65% for Bionano Genomics Inc (BNGO). The simple moving average for the past 20 days is -2.23% for BNGO’s stock, with a -66.41% simple moving average for the past 200 days.
Analysts’ Opinion of BNGO
BTIG Research gave a rating of “Buy” to BNGO, setting the target price at $3.50 in the report published on December 12th of the previous year.
BNGO Trading at -8.90% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.85% of loss for the given period.
Volatility was left at 4.65%, however, over the last 30 days, the volatility rate increased by 4.45%, as shares sank -8.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.75% lower at present.
During the last 5 trading sessions, BNGO rose by +2.43%, which changed the moving average for the period of 200-days by -86.94% in comparison to the 20-day moving average, which settled at $3.45. In addition, Bionano Genomics Inc saw -91.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Bionano Genomics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -2.86% for the present operating margin
- 0.03% for the gross margin
The net margin for Bionano Genomics Inc stands at -2.94%. The total capital return value is set at -1.56%. Equity return is now at value -127.82%, with -70.81% for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -2.37. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is -856.05.
Currently, EBITDA for the company is -97.47 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.93. The receivables turnover for the company is 8.49for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
To wrap up, the performance of Bionano Genomics Inc (BNGO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
